Form 4 for XLO Xilio Therapeutics, Inc.
Accepted 2025-01-03 00:00:00 ET · period of report 2025-01-01 · accession 0001415889-25-000405 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-03 | 2025-01-01 | XLO | Russo Rene | Pres AND CEO, Dir | M - OptEx | — | +44.2K | 244.9K | +22% | — |
| D | 2025-01-03 | 2025-01-01 | XLO | Russo Rene | Pres AND CEO, Dir | M - OptEx | $0.00 | -44.2K | 132.8K | -25% | $0 |
| D | 2025-01-03 | 2025-01-01 | XLO | Russo Rene | Pres AND CEO, Dir | A - Grant | $0.00 | +638.0K | 638.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-01 | M | A | 44,250 | — | 244,883 | D | — | — | (F1) Restricted stock units ("RSUs) convert to stock on a one-for-one basis |
| 2 | Derivative | Restricted Stock Units | 2025-01-01 | M | D | 44,250 | $0.00 | 132,750 | D | — · — to — | 44,250 Common Stock | (F1) Restricted stock units ("RSUs) convert to stock on a one-for-one basis (F2) These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. |
| 3 | Derivative | Stock Option (right to buy) | 2025-01-01 | A | A | 638,000 | $0.00 | 638,000 | D | $0.96 · — to 2035-12-31 | 638,000 Common Stock | (F3) The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029. |